Blog

Blog

Drug Target Encyclopedia Series (41) —BAFF

Linkedin

Release Time：

2026-07-10 14:19

 

  

BAFF, also known as B-cell Activating Factor or TNFSF13B, is a member of the TNF ligand superfamily and an important immune regulatory molecule involved in B-cell survival, maturation, and antibody production.

BAFF exists as both a membrane-bound protein and a soluble cytokine, interacting with receptors including BAFF-R, TACI, and BCMA to regulate B-cell homeostasis and humoral immune responses. Dysregulated BAFF signaling is closely associated with autoimmune diseases, B-cell malignancies, and chronic inflammatory disorders.

🧬 BAFF is highly relevant in:

• Systemic lupus erythematosus

• Sjögren’s syndrome

• Rheumatoid arthritis

• Multiple sclerosis

• B-cell malignancies

• Autoimmune and inflammatory disease research

🎯 Targeting BAFF in drug development:

  1. Monoclonal antibodies – Neutralize BAFF activity to reduce abnormal B-cell survival and autoantibody production.
  2. Receptor-Fc fusion proteins – Block BAFF/APRIL-related signaling pathways by trapping soluble ligands.
  3. Bispecific or dual-target strategies – Explore BAFF-related pathways together with APRIL, CD20, CD19, or other B-cell targets.
  4. Cell-based functional assays – Evaluate BAFF-mediated B-cell activation, proliferation, survival, and antibody secretion.
  5. Autoimmune disease strategies – Modulate BAFF-driven B-cell responses to restore immune balance.

💥 Challenges include:

• Complex biology of membrane-bound and soluble BAFF

• Functional overlap with APRIL signaling

• Disease heterogeneity and biomarker selection

• Balancing B-cell suppression with infection risk

• Optimizing therapeutic format, dosing, and patient stratification

🔬 BAFF is gaining continuous attention as a key B-cell regulatory target in autoimmune and inflammatory disease drug discovery. As antibody, fusion protein, and next-generation immune-modulating strategies continue to evolve, BAFF remains an important target for understanding and controlling pathological B-cell responses.

🔍 Is BAFF part of your immuno-oncology or immune modulation drug discovery pipeline?

 

Fill out the form below, or visit the link: to browse the complete list of available in-stock products.  

 

Prev

Drug Target Encyclopedia Series (42) —PCSK9

Drug Target Encyclopedia Series (40) —CD80

Next